Bioprinting novel 3D tissues with human ES-derived pancreatic beta cells to regulate blood glucose via the appropriate release of insulin

点击翻译按钮获取中文摘要

The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived betacells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasingcapability. The project represents a new collaboration between two leading Canadian technology developers:Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprintingtechnology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developedfor the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab willprovide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyond(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structuresusing Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized forcell viability, maturation, and insulin production in response to nutrients, both in vitro and following implantinto mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing theimmunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunityfor students in cutting edge biomedical engineering at the interface of academia and industry, and could lead tosubstantial investments in follow-up research and development.